Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study)

  • Clinical Investigation
  • Published:
Graefe's Archive for Clinical and Experimental Ophthalmology Aims and scope Submit manuscript

Abstract

Background

A novel alternative for combined treatment using verteporfin photodynamic therapy (PDT) has emerged as preliminary safety and efficacy data of the intravitreal use of the anti-angiogenic bevacizumab became available. In the current study we investigate the feasibility of intravitreal bevacizumab combined with verteporfin PDT for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods

A single-centre, prospective, open-label study of 11 patients with documented CNV progression after PDT treatment who underwent combined PDT and intravitreal injection of 1.5 mg of bevacizumab was undertaken. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 2, 12 and 24. Clinical evidence of complications and changes in logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts and in fluorescein leakage from CNV were evaluated.

Results

The mean (±SD) age of the 11 patients was 74 (±5) years. Seven eyes had been treated with one previous PDT session and four eyes had two previous PDT sessions. The mean baseline logMAR ETDRS BCVA was 1.031 (Snellen equivalent, 20/200−2). At follow-up weeks 1, 2, 12 and 24, the mean logMAR ETDRS BCVA (Snellen equivalent) was 0.944 (20/160−2), 0.924 (20/160−1), 0.882 (20/160+1), and 0.933 (20/160−2), respectively. The change in BCVA from baseline was significant at each study follow-up interval (P ≤ 0.001); at 12 and 24 weeks, the mean change in BCVA from baseline was an improvement of 1.49 and of 0.98 ETDRS line, respectively. Fluorescein leakage from CNV was absent in all eyes at week 12. One additional treatment session was required in seven (63.6%) eyes at week 24 due to recurrent fluorescein leakage from CNV (“minimum” [<50% of the leaking area noted at baseline], n = 4; and “moderate” [>50% of the leaking area noted at baseline], n = 3). No progression of the neovascular lesion was observed at week 24. No safety issues were identified throughout the period of the study.

Conclusions

The overall changes in vision and fluorescein leakage from CNV throughout the study suggest that a possible synergistic effect may arise from the combination of intravitreal bevacizumab with verteporfin PDT for the treatment of neovascular AMD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Miller JW, Schmidt-Erfurth U, Sickenberg M et al (1999) Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 117:1161–1173

    PubMed  CAS  Google Scholar 

  2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials-TAP report no. 1. Arch Ophthalmol 117:1329–1345

    Google Scholar 

  3. Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report no. 2. Arch Ophthalmol 119:198–207

    PubMed  CAS  Google Scholar 

  4. Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-VIP report no. 1. Ophthalmology 108:841–852

    Article  Google Scholar 

  5. Blinder KJ, Blumenkranz MS, Bressler NM et al (2003) Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 110:667–673

    Article  PubMed  Google Scholar 

  6. Gragoudas ES, Adamis AP, Cunningham ET Jr, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group et al (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816

    Article  PubMed  CAS  Google Scholar 

  7. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group (2005) Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina 25:815–827

    Article  Google Scholar 

  8. Rosenfeld PJ, Brown DM, Heier JS, MARINA Study Group et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431

    Article  PubMed  CAS  Google Scholar 

  9. Brown DM, Kaiser PK, Michels M, ANCHOR Study Group et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444

    Article  PubMed  CAS  Google Scholar 

  10. Rechtman E, Danis RP, Pratt LM, Harris A (2004) Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol 88:344–347

    Article  PubMed  CAS  Google Scholar 

  11. Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 110:1517–1525

    Article  PubMed  Google Scholar 

  12. Spaide RF, Sorenson J, Maranan L (2005) Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 112:301–304

    Article  PubMed  Google Scholar 

  13. Nicolo M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G (2006) Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina 26:58–64

    Article  PubMed  Google Scholar 

  14. Viola F, Morescalchi F, Ratiglia R, Staurenghi G (2006) Ptosis following an intravitreal injection of triamcinolone acetonide. Eye 2006 Feb 24 [Epub ahead of print]

  15. Aggermann T, Stolba U, Brunner S, Binder S (2006) Endophthalmitis with retinal necrosis following intravitreal triamcinolone acetonide injection. Ophthalmologica 220:131–133

    Article  PubMed  Google Scholar 

  16. Quiram PA, Gonzales CR, Schwartz SD (2006) Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 141:580–582

    Article  PubMed  CAS  Google Scholar 

  17. Saidel MA, Berreen J, Margolis TP (2005) Cytomegalovirus retinitis after intravitreous triamcinolone in an immunocompetent patient. Am J Ophthalmol 140:1141–1143

    Article  PubMed  Google Scholar 

  18. Yang CS, Chen MJ, Chou CK, Hsu WM (2005) Refractory severe ocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmologica 219:413–415

    Article  PubMed  Google Scholar 

  19. Gupta OP, Boynton JR, Sabini P, Markowitch W Jr, Quatela V (2003) Proptosis after retrobulbar corticosteroid injections. Ophthalmology 110:443–447

    Article  PubMed  Google Scholar 

  20. Dal Canto AJ, Downs-Kelly E, Perry JD (2005) Ptosis and orbital fat prolapse after posterior sub-Tenon’s capsule triamcinolone injection. Ophthalmology 112:1092–1097

    Article  PubMed  Google Scholar 

  21. Moshfeghi DM, Lowder CY, Roth DB, Kaiser PK (2002) Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol 134:132–134

    Article  PubMed  Google Scholar 

  22. Agrawal S, Agrawal J, Agrawal TP (2003) Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol 136:539–540

    Article  PubMed  Google Scholar 

  23. Eyetech Study Group (2002) Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22:143–152

    Article  Google Scholar 

  24. Eyetech Study Group (2003) Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110:979–986

    Article  Google Scholar 

  25. Kim IK, Husain D, Michaud N et al (2006) Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci 47:357–363

    Article  PubMed  Google Scholar 

  26. Husain D, Kim I, Gauthier D et al (2005) Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 123:509–516

    Article  PubMed  Google Scholar 

  27. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO (2003) Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 44:4473–4480

    Article  PubMed  Google Scholar 

  28. Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  PubMed  CAS  Google Scholar 

  29. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  PubMed  CAS  Google Scholar 

  30. Shahar J, Avery RL, Heilweil G et al (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26:262–269

    Article  PubMed  Google Scholar 

  31. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26:270–274

    Article  PubMed  Google Scholar 

  32. Manzano RP, Peyman GA, Khan P, Kivilcim M (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26:257–261

    Article  PubMed  Google Scholar 

  33. Rosenfeld PJ, Moshfeghi AA, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 36:331–335

    PubMed  Google Scholar 

  34. Rosenfeld PJ, Fung AE, Puliafito CA (2005) Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 36:336–339

    PubMed  Google Scholar 

  35. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113:363–372

    Article  PubMed  Google Scholar 

  36. Spaide RF, Laud K, Fine HF et al (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390

    Article  PubMed  Google Scholar 

  37. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo LA, Scott IU (2006) Intravitreal bevacizumab (Avastin) for choroidal neovascularization caused by age-related macular degeneration (IBeNA Study): results of a dose-escalation study. Invest Ophthalmol Vis Sci 47:4569–4578

    Article  PubMed  Google Scholar 

  38. Iturralde D, Spaide RF, Meyerle CB et al (2006) Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26:279–284

    Article  PubMed  Google Scholar 

  39. Paula JS, Jorge R, Costa RA, Rodrigues MLV, Scott IU (2006) Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 84:556–557

    Article  Google Scholar 

  40. Spaide RF, Fisher YL (2006) Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26:275–278

    Article  PubMed  Google Scholar 

  41. Jorge R, Costa RA, Calucci D, Cintra L, Scott IU (2006) Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBePe Study). Retina 26:1006–1013

    Article  PubMed  Google Scholar 

  42. Bird AC, Bressler NM, Bressler SB et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39:367–374

    Article  PubMed  CAS  Google Scholar 

  43. Verteporfin in Photodynamic Therapy Study Group (2001) Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial. VIP report no 1. Ophthalmology 108:841–852

    Article  Google Scholar 

  44. Henderson BW, Dougherty TJ (1992) How does photodynamic therapy work? Photochem Photobiol 55:145–157

    PubMed  CAS  Google Scholar 

  45. Grossweiner LI (1994) The science of phototherapy. CRC Press, Boca Raton, FL, USA, pp 27–49, 139–155, 175–177

  46. Costa RA, Farah ME, Cardillo JA, Calucci DS, Williams GA (2003) Immediate indocyanine green angiography and optical coherence tomography evaluation after photodynamic therapy of subfoveal choroidal neovascularization. Retina 23:159–165

    Article  PubMed  Google Scholar 

  47. Schmidt-Erfurth U, Laqua H, Schloetzer-Schrehard U et al (2002) Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 120:835–843

    PubMed  Google Scholar 

  48. Gelisken F, Lafaut BA, Inhoffen W et al (2004) Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy. Br J Ophthalmol 88:207–211

    Article  PubMed  CAS  Google Scholar 

  49. Schnurrbusch UEK, Welt K, Horn LC et al (2001) Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 85:1086–1091

    Article  PubMed  CAS  Google Scholar 

  50. Ghazi NG, Jabbour NM, De la Cruz ZC et al (2001) Clinicopathologic studies of age-related macular degeneration with classic subfoveal choroidal neovascularization treated with photodynamic therapy. Retina 21:478–486

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. U.D.A.T. Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Rua Padre Duarte 989 apto 172, Araraquara, SP, 14801-310, Brazil

    Rogério A. Costa, Daniela Calucci, Luiz A. S. Melo Jr. & José A. Cardillo

  2. Retina and Vitreous Section, Department of Ophthalmology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, SP, Brazil

    Rogério A. Costa & Rodrigo Jorge

  3. Departments of Ophthalmology and Health Evaluation Sciences, Penn State College of Medicine, Hershey, PA, USA

    Ingrid U. Scott

Authors
  1. Rogério A. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodrigo Jorge
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniela Calucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Luiz A. S. Melo Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. José A. Cardillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ingrid U. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rogério A. Costa.

Additional information

In terms of funding, this was an investigator’s driven study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costa, R.A., Jorge, R., Calucci, D. et al. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Graefes Arch Clin Exp Ophthalmol 245, 1273–1280 (2007). https://doi.org/10.1007/s00417-007-0557-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-007-0557-x

Keywords

Search

Navigation